hydrochlorothiazide has been researched along with Melanoma in 16 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "There are concerns that hydrochlorothiazide may increase the risk of incident nonmelanoma (cutaneous squamous cell carcinoma [cSCC], basal cell carcinoma [BCC]) and melanoma skin cancer, with regulatory agencies and societies calling for additional studies." | 8.02 | Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. ( Azoulay, L; Nirantharakumar, K; Pottegård, A; Rouette, J; Yin, H, 2021) |
| "In 2018, the Pharmacological Risk Assessment Committee alerted to a potential relationship between accumulated hydrochlorothiazide dosage and the risk of non-melanoma skin cancer." | 8.02 | Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. ( Lecaros-Astorga, DA; Martin-Arias, LH; Molina-Guarneros, JA; Rodríguez-Jiménez, P; Sainz-Gil, M, 2021) |
| "Hydrochlorothiazide (HCTZ), a common diuretic known to be photosensitizing and previously associated with non-melanoma skin cancer, was recently reported to be associated with two melanoma subtypes, nodular and lentigo, among residents of Denmark." | 8.02 | Hydrochlorothiazide and risk of melanoma subtypes. ( Achacoso, N; Fireman, B; Habel, LA; Pedersen, SA; Pottegård, A, 2021) |
| "Recent studies reported the association between increased risk of nonmelanoma skin cancers (NMSCs) and the use of hydrochlorothiazide (HCTZ), one of the most commonly prescribed diuretic, antihypertensive drug, over the world." | 8.02 | Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study. ( Bigagli, E; Cinci, L; Colucci, R; D'Ambrosio, M; Lodovici, M; Luceri, C; Mugelli, A; Nardini, P; Portelli, F, 2021) |
| "Hydrochlorothiazide is associated with an increased risk for NMSC (especially SCC) and melanoma in non-Asian countries, whereas bendroflumethiazide and indapamide are not associated with a meaningful risk for skin cancers." | 5.22 | Associations of thiazide use with skin cancers: a systematic review and meta-analysis. ( Chen, YH; Chi, CC; Hung, MJ; Lai, CC; Lai, EC; Shao, SC, 2022) |
| "There are concerns that hydrochlorothiazide may increase the risk of incident nonmelanoma (cutaneous squamous cell carcinoma [cSCC], basal cell carcinoma [BCC]) and melanoma skin cancer, with regulatory agencies and societies calling for additional studies." | 4.02 | Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. ( Azoulay, L; Nirantharakumar, K; Pottegård, A; Rouette, J; Yin, H, 2021) |
| "In 2018, the Pharmacological Risk Assessment Committee alerted to a potential relationship between accumulated hydrochlorothiazide dosage and the risk of non-melanoma skin cancer." | 4.02 | Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. ( Lecaros-Astorga, DA; Martin-Arias, LH; Molina-Guarneros, JA; Rodríguez-Jiménez, P; Sainz-Gil, M, 2021) |
| "Hydrochlorothiazide (HCTZ), a common diuretic known to be photosensitizing and previously associated with non-melanoma skin cancer, was recently reported to be associated with two melanoma subtypes, nodular and lentigo, among residents of Denmark." | 4.02 | Hydrochlorothiazide and risk of melanoma subtypes. ( Achacoso, N; Fireman, B; Habel, LA; Pedersen, SA; Pottegård, A, 2021) |
| "Recent studies reported the association between increased risk of nonmelanoma skin cancers (NMSCs) and the use of hydrochlorothiazide (HCTZ), one of the most commonly prescribed diuretic, antihypertensive drug, over the world." | 4.02 | Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study. ( Bigagli, E; Cinci, L; Colucci, R; D'Ambrosio, M; Lodovici, M; Luceri, C; Mugelli, A; Nardini, P; Portelli, F, 2021) |
| "The antihypertensive agent hydrochlorothiazide has been associated with increased risks of non-melanoma skin cancer (NMSC) and possibly some melanoma subtypes." | 3.91 | Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study. ( Hsu, CK; Lai, EC; Lee, CN; Liao, TC; Pedersen, SA; Pottegård, A; Schmidt, SAJ; Shao, SC, 2019) |
| "We found no increased skin cancer risk when analyzing cohort studies or studies that corrected for important covariates." | 3.01 | The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis. ( Daams, JG; de Rie, MA; Heisel, AGU; Olde Engberink, RHG; van den Born, BH; Vogt, L; Vuurboom, MD, 2023) |
| " These results do not modify the benefit/risk ratio but should lead to propose preventive mesures: identification of high risk population, avoidance of this drug if possible in immunocompromised patients or with previous skin cancer, regular skin examination in case of long term use of hydrochlorothiazide." | 2.61 | [Hydrochlorothiazide use and risk of skin cancers: A systematic review]. ( Becquart, O; Bourrain, JL; Du-Thanh, A; Duflos, C; Guillot, B, 2019) |
| "We evaluated melanoma and nonmelanoma skin cancer among hydrochlorothiazide users with 3 different cohorts as each allows assessment of different potential cofounders/effect modifiers, including race/ethnicity." | 1.91 | Skin Cancer and Hydrochlorothiazide: Novel Population-Based Analyses Considering Personal Risk Factors Including Race/Ethnicity. ( Abrahamowicz, M; Bernatsky, S; Birck, MG; Liu, JL; Machado, MAA; Moura, CS; Pilote, L, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 10 (62.50) | 2.80 |
| Authors | Studies |
|---|---|
| Shao, SC | 2 |
| Lai, CC | 1 |
| Chen, YH | 1 |
| Lai, EC | 2 |
| Hung, MJ | 1 |
| Chi, CC | 1 |
| Heisel, AGU | 1 |
| Vuurboom, MD | 1 |
| Daams, JG | 1 |
| de Rie, MA | 1 |
| Vogt, L | 2 |
| van den Born, BH | 2 |
| Olde Engberink, RHG | 1 |
| Azoulay, L | 2 |
| St-Jean, A | 1 |
| Dahl, M | 1 |
| Quail, J | 1 |
| Aibibula, W | 1 |
| Brophy, JM | 1 |
| Chan, AW | 1 |
| Bresee, L | 1 |
| Carney, G | 1 |
| Eltonsy, S | 1 |
| Tamim, H | 1 |
| Paterson, JM | 1 |
| Platt, RW | 1 |
| Birck, MG | 1 |
| Moura, CS | 1 |
| Machado, MAA | 1 |
| Liu, JL | 1 |
| Abrahamowicz, M | 1 |
| Pilote, L | 1 |
| Bernatsky, S | 1 |
| Pottegård, A | 7 |
| Pedersen, SA | 4 |
| Schmidt, SAJ | 2 |
| Lee, CN | 1 |
| Hsu, CK | 1 |
| Liao, TC | 1 |
| Cognetta, A | 1 |
| Kristensen, KB | 1 |
| Daniels, B | 1 |
| Pearson, SA | 1 |
| Vajdic, CM | 1 |
| Buckley, NA | 1 |
| Zoega, H | 1 |
| Rouette, J | 1 |
| Yin, H | 1 |
| Nirantharakumar, K | 1 |
| Lecaros-Astorga, DA | 1 |
| Molina-Guarneros, JA | 1 |
| Rodríguez-Jiménez, P | 1 |
| Martin-Arias, LH | 1 |
| Sainz-Gil, M | 1 |
| Habel, LA | 1 |
| Achacoso, N | 1 |
| Fireman, B | 1 |
| Bigagli, E | 1 |
| Cinci, L | 1 |
| D'Ambrosio, M | 1 |
| Nardini, P | 1 |
| Portelli, F | 1 |
| Colucci, R | 1 |
| Lodovici, M | 1 |
| Mugelli, A | 1 |
| Luceri, C | 1 |
| Hölmich, LR | 1 |
| Friis, S | 1 |
| Gaist, D | 2 |
| Schmutz, JL | 1 |
| Olde-Engberink, R | 1 |
| Becquart, O | 1 |
| Guillot, B | 1 |
| Bourrain, JL | 1 |
| Duflos, C | 1 |
| Du-Thanh, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Hydrochlorothiazide and the Risk of Skin Cancer[NCT04334824] | 2,953,748 participants (Actual) | Observational | 2019-05-27 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for hydrochlorothiazide and Melanoma
| Article | Year |
|---|---|
Associations of thiazide use with skin cancers: a systematic review and meta-analysis.
Topics: Bendroflumethiazide; Carcinoma, Squamous Cell; Humans; Hydrochlorothiazide; Indapamide; Melanoma; Sk | 2022 |
The use of specific antihypertensive medication and skin cancer risk: A systematic review of the literature and meta-analysis.
Topics: Antihypertensive Agents; Diuretics; Humans; Hydrochlorothiazide; Hypertension; Melanoma; Skin Neopla | 2023 |
Hydrochlorothiazide use and risk of keratinocyte carcinoma and melanoma: A multisite population-based cohort study.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Canada; | 2023 |
[Hydrochlorothiazide use and risk of skin cancers: A systematic review].
Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Hydrochlorothiazide; Melanoma; Risk Assessm | 2019 |
12 other studies available for hydrochlorothiazide and Melanoma
| Article | Year |
|---|---|
Skin Cancer and Hydrochlorothiazide: Novel Population-Based Analyses Considering Personal Risk Factors Including Race/Ethnicity.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ethnicity; Humans; Hydroch | 2023 |
Use of hydrochlorothiazide and risk of skin cancer: a nationwide Taiwanese case-control study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Case-Control Studies; Female; Humans; Hydrochlorot | 2019 |
No association between hydrochlorothiazide use and uveal melanoma.
Topics: Antihypertensive Agents; Case-Control Studies; Female; Humans; Hydrochlorothiazide; Male; Melanoma; | 2020 |
Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study.
Topics: Aged; Aged, 80 and over; Australia; Carcinoma, Squamous Cell; Case-Control Studies; Cohort Studies; | 2020 |
Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer.
Topics: Cohort Studies; Humans; Hydrochlorothiazide; Melanoma; Risk Assessment; Skin Neoplasms; Sodium Chlor | 2021 |
Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study.
Topics: Carcinoma, Basal Cell; Humans; Hydrochlorothiazide; Melanoma; Risk Factors; Skin Neoplasms; Spain | 2021 |
Hydrochlorothiazide and risk of melanoma subtypes.
Topics: Diuretics; Educational Status; Humans; Hydrochlorothiazide; Logistic Models; Melanoma | 2021 |
Hydrochlorothiazide Use and Risk of Nonmelanoma Skin Cancers: A Biological Plausibility Study.
Topics: Cell Line; DNA Damage; Humans; Hydrochlorothiazide; Keratinocytes; Melanoma; Oxidative Stress; Skin | 2021 |
Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Female; Humans; Hydrochlorothiazide; Male; Melan | 2018 |
[Hydrochlorothiazide appears to increase risk of melanoma].
Topics: Humans; Hydrochlorothiazide; Melanoma; Skin Neoplasms | 2018 |
Hydrochlorothiazide and the Risk of Malignant Melanoma.
Topics: Humans; Hydrochlorothiazide; Melanoma; Skin Neoplasms | 2018 |
Hydrochlorothiazide and the Risk of Malignant Melanoma-Reply.
Topics: Humans; Hydrochlorothiazide; Melanoma; Skin Neoplasms | 2018 |